MRI Method Predicts Early Response
October 1st 2001NEW ORLEANS-Diffusion-weighted MRI reveals rapid changes in tumor water diffusion values after successful therapeutic intervention in solid tumors. It therefore appears capable of predicting treatment response within days of initiating therapy, Brian D. Ross, PhD, of the University of Michigan, said at the 92nd Annual Meeting of the American Association for Cancer Research (AACR).
New Cellular Target Shows Promise in Cancer Treatment
October 1st 2001SAN FRANCISCO-Aberrant responses to growth signals lead to the development of several types of cancer. The mammalian target of rapamycin (mTOR) is a protein kinase involved in the signal transduction pathway that links growth stimuli and cell cycle progression. It has emerged as a promising new target for intervening in the cancer process.
Post-HAART HIV+ NHL Patients Benefit From Chemotherapy
October 1st 2001SAN FRANCISCO-HIV-positive patients with non-Hodgkin’s lymphoma (NHL) should not be excluded from chemotherapy or given a limited-dose regimen, Joseph Sparano, MD, said at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1172).
Agency Considers Agents for Listing as Known or Likely Human Carcinogens
October 1st 2001RESEARCH TRIANGLE PARK, North Carolina-Sixteen chemicals and other agents will undergo toxicologic review by the National Toxicology Program for possible listing as known or reasonably anticipated to be human carcinogens in the 11th edition of the federal Report on Carcinogens.
Breast Conservation Effective in Occult Primary Cancer With Axillary Metastases
October 1st 2001WASHINGTON-Mastectomy does not improve either survival or local control when patients present with axillary node metastases and an occult primary tumor, Georges Vlastos, MD, of Geneva University Hospital, Geneva, Switzerland, said at the 54th Annual Cancer Symposium of the Society of Surgical Oncology. He described a retrospective study of 45 women with this rare condition, conducted when he was at M. D. Anderson Cancer Center.
Raloxifene Not Recommended After Tamoxifen Failure
October 1st 2001SAN FRANCISCO-Five years of tamoxifen (Nolvadex) is standard treatment for many women with estrogen-receptor (ER)-sensitive breast cancer, but the question of what to do after that is unresolved. Raloxifene (Evista) has been considered by some researchers as a possible next treatment, but preclinical data suggest this will not be a successful strategy. Ruth M. O’Regan, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, presented the data at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 95).
Tobacco Money Pot: Half Full or Half Empty?
October 1st 2001WASHINGTON-More than beauty lies in the eye of the beholder. For example, the National Conference of State Legislatures (NCSL) and the Campaign for Tobacco Free Kids offered quite different interpretations of a report released by NCSL at its annual meeting.
Studies Seek to Find Female Biologic Factors That Affect HIV
October 1st 2001BETHESDA, Maryland-A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.
ONI Names Sharon Krumm, PhD, RN, Editor of Oncology Nursing
October 1st 2001MELVILLE, New York-The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.
Ibandronate vs Pamidronate in the Treatment of Malignant Hypercalcemia
October 1st 2001Data from the first study to compare ibandronate with pamidronate (Aredia) in the treatment of malignant hypercalcemia were presented at the 37th annual meeting of the American Society of Clinical Oncology. The results demonstrated that rates
Many More Patients Will Be Needed for Trials of the Future
October 1st 2001BOSTON-Targeted anticancer drugs such as trastuzumab (Herceptin) targeting HER-2 and imatinib mesylate (Gleevec) targeting Bcr-Abl represent the potential of genome-based medicine, but the future may not be as close as it seems, according to pharmaceutical executives who spoke at the 2001 Drug Discovery Technology Conference.
FDA Approves Zoledronic Acid for the Treatment of Hypercalcemia of Malignancy
October 1st 2001Novartis announced recently that it received marketing approval from the US Food and Drug Administration (FDA) for zoledronic acid (Zometa), a new generation intravenous bisphosphonate for the treatment of hypercalcemia of malignancy.
Battling Fatigue With Exercise Program and Good Nutrition
October 1st 2001NEW YORK-Keeping fit and eating right is no easy task for the millions of Americans who are overweight and out of shape. For cancer patients, it requires specialized know-how as well as determination, according to experts who gave advice during a Cancer Care, Inc. teleconference on ways to battle fatigue.
HAART Improves Survival in Chemotherapy-Treated, HIV-Related NHL
October 1st 2001SAN FRANCISCO-Use of highly active antiretroviral therapy (HAART) significantly increases disease-free survival among patients with HIV-related non-Hodgkin’s lymphoma (NHL), Michele Spina, MD, of Centro di Riferimento Oncologico, Aviano, Italy, said at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1122).
Zometa for Hypercalcemia of Malignancy
October 1st 2001ROCKVILLE, Maryland-Zometa (zoledronic acid for injection) has received marketing approval from the US Food and Drug Administration for the treatment of hypercalcemia of malignancy. Zoledronic acid represents a new generation of intravenous bisphosphonates. It is currently approved for treating hypercalcemia of malignancy in more than 30 countries.
Rituximab Added to Fludarabine in Untreated CLL Patients
October 1st 2001SAN FRANCISCO-Preliminary results from the Cancer and Leukemia Group B (CALGB)-9712 trial indicate that rituximab (Rituxan) given concurrently with fludarabine (Fludara) improves response in previously untreated chronic lymphocytic leukemia (CLL) patients, compared with a sequential approach. The results were presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1116).
Large-Core Needle Biopsy Reduces Need for Surgical Biopsies
October 1st 2001SEATTLE-A fully implemented large-core needle biopsy program can dramatically improve the positive predictive value of surgical biopsy of breast lesions, based on the experience of the Brigham and Women’s Hospital, Boston. Jessica Leung, MD, instructor in radiology, Harvard Medical School, presented the study at the 101st Annual Meeting of the American Roentgen Ray Society.
Shorter Follow-up for Aspiration-Negative Breast Masses
October 1st 2001SEATTLE-A 1-year follow-up with mammography appears to be sufficient to detect any false-negative results of ultrasound-guided fine-needle aspiration in patients with nonpalpable breast masses, according to a study from the Montefiore Medical Center, Bronx, NY. Shalom Buchbinder, MD, director of mammography, presented the study at the 101st Annual Meeting of the American Roentgen Ray Society.
Prevalence of Complementary and Alternative Medicine Use in Cancer Patients
October 1st 2001Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was
Patterns of Chemotherapy Administration in Patients With Intermediate-Grade Non-Hodgkin’s Lymphoma
October 1st 2001Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-
Prevalence of Complementary and Alternative Medicine Use in Cancer Patients
October 1st 2001Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was
Prevalence of Complementary and Alternative Medicine Use in Cancer Patients
October 1st 2001Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was
Prevalence of Complementary and Alternative Medicine Use in Cancer Patients
October 1st 2001Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was
Patterns of Chemotherapy Administration in Patients With Intermediate-Grade Non-Hodgkin’s Lymphoma
Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-
Patterns of Chemotherapy Administration in Patients With Intermediate-Grade Non-Hodgkin’s Lymphoma
October 1st 2001Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-